Search

Your search keyword '"Windsor, Ian W."' showing total 29 results
Start Over Author "Windsor, Ian W."
29 results on '"Windsor, Ian W."'

1. Structural basis for CCR6 modulation by allosteric antagonists

Author

Wasilko, David Jonathan, Gerstenberger, Brian S., Farley, Kathleen A., Li, Wei, Alley, Jennifer, Schnute, Mark E., Unwalla, Ray J., Victorino, Jorge, Crouse, Kimberly K., Ding, Ru, Sahasrabudhe, Parag V., Vincent, Fabien, Frisbie, Richard K., Dermenci, Alpay, Flick, Andrew, Choi, Chulho, Chinigo, Gary, Mousseau, James J., Trujillo, John I., Nuhant, Philippe, Mondal, Prolay, Lombardo, Vincent, Lamb, Daniel, Hogan, Barbara J., Minhas, Gurdeep Singh, Segala, Elena, Oswald, Christine, Windsor, Ian W., Han, Seungil, Rappas, Mathieu, Cooke, Robert M., Calabrese, Matthew F., Berstein, Gabriel, Thorarensen, Atli, and Wu, Huixian

Published
2024
Full Text
View/download PDF

2. An epitope-enriched immunogen expands responses to a conserved viral site

Author

Caradonna, Timothy M., Ronsard, Larance, Yousif, Ashraf S., Windsor, Ian W., Hecht, Rachel, Bracamonte-Moreno, Thalia, Roffler, Anne A., Maron, Max J., Maurer, Daniel P., Feldman, Jared, Marchiori, Elisa, Barnes, Ralston M., Rohrer, Daniel, Lonberg, Nils, Oguin, Thomas H., III, Sempowski, Gregory D., Kepler, Thomas B., Kuraoka, Masayuki, Lingwood, Daniel, and Schmidt, Aaron G.

Published
2022
Full Text
View/download PDF

4. A non-neutralizing glycoprotein B monoclonal antibody protects against herpes simplex virus disease in mice

Author

Kuraoka, Masayuki, Aschner, Clare Burn, Windsor, Ian W., Mahant, Aakash Mahant, Garforth, Scott J., Kong, Susan Luozheng, Achkar, Jacqueline M., Almo, Steven C., Kelsoe, Garnett, and Herold, Betsy C.

Subjects
Glycoproteins -- Health aspects, Herpes simplex -- Drug therapy, Herpesvirus vaccines -- Research, Pharmaceutical research, Monoclonal antibodies -- Research, Health care industry
Abstract

There is an unmet need for monoclonal antibodies (mAbs) for prevention or as adjunctive treatment of herpes simplex virus (HSV) disease. Most vaccine and mAb efforts focus on neutralizing antibodies, but for HSV this strategy has proven ineffective. Preclinical studies with a candidate HSV vaccine strain, [DELTA]gD-2, demonstrated that non-neutralizing antibodies that activate Fc[gamma] receptors (Fc[gamma]Rs) to mediate antibody-dependent cellular cytotoxicity (ADCC) provide active and passive protection against HSV-1 and HSV-2. We hypothesized that this vaccine provides a tool to identify and characterize protective mAbs. We isolated HSV-specific mAbs from germinal center and memory B cells and bone marrow plasmacytes of [DELTA]gD-2- vaccinated mice and evaluated these mAbs for binding, neutralizing, and Fc[gamma]R-activating activity and for protective efficacy in mice. The most potent protective mAb, BMPC-23, was not neutralizing but activated murine Fc[gamma]RIV, a biomarker of ADCC. The cryo-electron microscopic structure of the Fab-glycoprotein B (gB) assembly identified domain IV of gB as the epitope. A single dose of BMPC-23 administered 24 hours before or after viral challenge provided significant protection when configured as mouse IgG2c and protected mice expressing human Fc[gamma]RIII when engineered as a human IgG1. These results highlight the importance of FcR-activating antibodies in protecting against HSV., Introduction Before the SARS-CoV-2 pandemic, few monoclonal antibodies (mAbs) had advanced into the clinic for treatment or prevention of infectious diseases, with the notable exception of palivizumab for respiratory syncytial [...]

Published
2023
Full Text
View/download PDF

8. Cross-reactive SARS-CoV-2 epitope targeted across donors informs immunogen design

Author

Hauser, Blake M., primary, Feldman, Jared, additional, Sangesland, Maya, additional, Ronsard, Larance, additional, St. Denis, Kerri J., additional, Sheehan, Maegan L., additional, Cao, Yi, additional, Boucau, Julie, additional, Windsor, Ian W., additional, Cheng, Agnes H., additional, Vu, Mya L., additional, Cardoso, Marcella R., additional, Kannegieter, Ty, additional, Balazs, Alejandro B., additional, Lingwood, Daniel, additional, Garcia-Beltran, Wilfredo F., additional, and Schmidt, Aaron G., additional

Published
2022
Full Text
View/download PDF

9. Antibodies induced by an ancestral SARS-CoV-2 strain that cross-neutralize variants from Alpha to Omicron BA.1

Author

Windsor, Ian W., primary, Tong, Pei, additional, Lavidor, Olivia, additional, Moghaddam, Ali Sanjari, additional, McKay, Lindsay G.A., additional, Gautam, Avneesh, additional, Chen, Yuezhou, additional, MacDonald, Elizabeth A., additional, Yoo, Duck Kyun, additional, Griffths, Anthony, additional, Wesemann, Duane R., additional, and Harrison, Stephen C., additional

Published
2022
Full Text
View/download PDF

10. Rationally designed immunogens enable immune focusing following SARS-CoV-2 spike imprinting

Author

Hauser, Blake M., primary, Sangesland, Maya, additional, St. Denis, Kerri J., additional, Lam, Evan C., additional, Case, James Brett, additional, Windsor, Ian W., additional, Feldman, Jared, additional, Caradonna, Timothy M., additional, Kannegieter, Ty, additional, Diamond, Michael S., additional, Balazs, Alejandro B., additional, Lingwood, Daniel, additional, and Schmidt, Aaron G., additional

Published
2022
Full Text
View/download PDF

11. Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike

Author

Tong, Pei, primary, Gautam, Avneesh, additional, Windsor, Ian W., additional, Travers, Meghan, additional, Chen, Yuezhou, additional, Garcia, Nicholas, additional, Whiteman, Noah B., additional, McKay, Lindsay G.A., additional, Storm, Nadia, additional, Malsick, Lauren E., additional, Honko, Anna N., additional, Lelis, Felipe J.N., additional, Habibi, Shaghayegh, additional, Jenni, Simon, additional, Cai, Yongfei, additional, Rennick, Linda J., additional, Duprex, W. Paul, additional, McCarthy, Kevin R., additional, Lavine, Christy L., additional, Zuo, Teng, additional, Lin, Junrui, additional, Zuiani, Adam, additional, Feldman, Jared, additional, MacDonald, Elizabeth A., additional, Hauser, Blake M., additional, Griffths, Anthony, additional, Seaman, Michael S., additional, Schmidt, Aaron G., additional, Chen, Bing, additional, Neuberg, Donna, additional, Bajic, Goran, additional, Harrison, Stephen C., additional, and Wesemann, Duane R., additional

Published
2021
Full Text
View/download PDF

13. Additional file 1 of Ribonuclease zymogen induces cytotoxicity upon HIV-1 infection

Author

Windsor, Ian W., Dudley, Dawn M., O’Connor, David H., and Raines, Ronald T.

Abstract

Additional file 1: Table S1. Str2-EV kinetic parameters at pH 5.0. Figure S1. Amino acid sequences of human RNase 1 and the cyclic Str2-EV zymogen. Figure S2. Inhibition of QBI-139 and Str2-EV by human RI. Figure S3. Inhibition of QBI-139 and Str2-EV by human RI. Figure S4. Hydrolysis of SGIFLETS peptide by MT-4 cell extract.

Published
2021
Full Text
View/download PDF

15. Rationally Designed Immunogens Enable Immune Focusing Following SARS-CoV-2 Spike Imprinting

Author

Hauser, Blake M., primary, Sangesland, Maya, additional, St. Denis, Kerri J., additional, Lam, Evan C., additional, Case, James Brett, additional, Windsor, Ian W., additional, Feldman, Jared, additional, Caradonna, Timothy M., additional, Kannegieter, Ty, additional, Diamond, Michael S., additional, Balazs, Alejandro Benjamin, additional, Lingwood, Daniel, additional, and Schmidt, Aaron, additional

Published
2021
Full Text
View/download PDF

28. Rationally designed immunogens enable immune focusing to the SARS-CoV-2 receptor binding motif.

Author

Hauser BM, Sangesland M, Denis KJS, Windsor IW, Feldman J, Lam EC, Kannegieter T, Balazs AB, Lingwood D, and Schmidt AG

Abstract

Eliciting antibodies to surface-exposed viral glycoproteins can lead to protective responses that ultimately control and prevent future infections. Targeting functionally conserved epitopes may help reduce the likelihood of viral escape and aid in preventing the spread of related viruses with pandemic potential. One such functionally conserved viral epitope is the site to which a receptor must bind to facilitate viral entry. Here, we leveraged rational immunogen design strategies to focus humoral responses to the receptor binding motif (RBM) on the SARS-CoV-2 spike. Using glycan engineering and epitope scaffolding, we find an improved targeting of the serum response to the RBM in context of SARS-CoV-2 spike imprinting. Furthermore, we observed a robust SARS-CoV-2-neutralizing serum response with increased potency against related sarbecoviruses, SARS-CoV, WIV1-CoV, RaTG13-CoV, and SHC014-CoV. Thus, RBM focusing is a promising strategy to elicit breadth across emerging sarbecoviruses and represents an adaptable design approach for targeting conserved epitopes on other viral glycoproteins., One Sentence Summary: SARS-CoV-2 immune focusing with engineered immunogens.

Published
2021
Full Text
View/download PDF

29. An n → π * Interaction in the Bound Substrate of Aspartic Proteases Replicates the Oxyanion Hole.

Author

Windsor IW, Gold B, and Raines RT

Abstract

Aspartic proteases regulate many biological processes and are prominent targets for therapeutic intervention. Structural studies have captured intermediates along the reaction pathway, including the Michaelis complex and tetrahedral intermediate. Using a Ramachandran analysis of these structures, we discovered that residues occupying the P1 and P1' positions (which flank the scissile peptide bond) adopt the dihedral angle of an inverse γ-turn and polyproline type-II helix, respectively. Computational analyses reveal that the polyproline type-II helix engenders an n → π * interaction in which the oxygen of the scissile peptide bond is the donor. This interaction stabilizes the negative charge that develops in the tetrahedral intermediate, much like the oxyanion hole of serine proteases. The inverse γ-turn serves to twist the scissile peptide bond, vacating the carbonyl π * orbital and facilitating its hydration. These previously unappreciated interactions entail a form of substrate-assisted catalysis and offer opportunities for drug design., Competing Interests: The authors declare no competing financial interest.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results